Breakthrough Trial Results Propel Assembly Biosciences into Spotlight

Assembly Biosciences delivered a stunning market surprise with exceptional clinical data for its investigational herpes treatment, ABI-5366. The biopharmaceutical company’s stock surged following the release of Phase 1b interim results that significantly exceeded projections.

Presented at the 38th Congress of the International Union Against Sexually Transmitted Infections in Athens, the findings demonstrated remarkable efficacy. The experimental compound ABI-5366 achieved a 94 percent reduction in HSV-2 viral shedding compared to placebo. The effect proved even more pronounced in cases with high viral load, where researchers observed a dramatic 98 percent decrease.

The compelling data arrives at a pivotal moment for Assembly Biosciences. The company has established a collaboration agreement with pharmaceutical leader Gilead Sciences, granting Gilead exclusive licensing rights upon completion... Read more...